Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term secondary prophylaxis with FVIII/VWF concentrate in severe inherited von Willebrand disease
2006-001383-23Phase 3Completed
- Sponsor
- Fondazione Angelo Bianchi Bonomi
- Start
- Nov 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of antihemophilic factor/von willebrand factor complex (human) in von Willebrand disease (VWD) (2 arms), sponsored by Fondazione Angelo Bianchi Bonomi. Primary endpoint: Prevention of spontaneous bleeding onset. Started Nov 2006; status: completed.
02
Drugs
antihemophilic factor/von willebrand factor complex (human)
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2006-001383-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001383-23.